Van ECK Associates Corp Sells 13,427 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Van ECK Associates Corp lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,133 shares of the biopharmaceutical company’s stock after selling 13,427 shares during the period. Van ECK Associates Corp’s holdings in Alnylam Pharmaceuticals were worth $18,757,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. OFI Invest Asset Management boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 22 shares in the last quarter. Howard Capital Management Inc. increased its holdings in Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC raised its position in Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC raised its position in Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 3.5% during the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,923 shares of company stock worth $18,072,087 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.1%

ALNY stock traded down $3.38 during trading on Friday, hitting $313.85. The company had a trading volume of 165,845 shares, compared to its average volume of 1,408,201. The business has a 50-day moving average of $346.09 and a 200-day moving average of $410.94. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The stock has a market cap of $41.62 billion, a PE ratio of 183.96 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.65) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALNY. Chardan Capital reduced their price target on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Leerink Partners cut their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Finally, Wells Fargo & Company dropped their price target on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.